Press release
Top 5 players in US Biosimilar Market
STORY OUTLINE• Pfizer: Excelling in the line of Biosimilar drugs with an experience of more than 10 years with presence in over 180 countries.
• Amgen: Making pharmaceutical products with an experience of over 40 years and presence in over 100 countries.
• Viartis: Presence in over 165 countries, and making Biosimilar drugs in over 75 markets, this pharmaceutical company is another leading contributor of US Biosimilar market.
• Coherus Biosciences: Increasing patient access to cost effective medicines with a Biosimilar drugs experience of 13 years.
• Biogen: serving humanity through science with a experiences of more than 40 years in the field of biologics.
• According to Ken Research, the US Biosimilar market is anticipated to grow at a CAGR of ~40% in the next five years which currently has a market size of ~USD 9.4 Bn.
The US Biosimilar market is rapidly growing and will be witnessing a significant growth in the next five years.
There are various reasons behind the rapid growth of US Biosimilar market. Some of the major reasons behind the growth of US Biosimilar market include the cost effective nature of Biosimilar drugs, rising geriatric population, rising prevalence of chronic diseases, and growing partnerships between companies to develop Biosimilar drugs.
Various companies and players are contributing to their best efforts in the growth of the US Biosimilar market.
This article aims to put light on the contributions done by the major players towards the growth of the US Biosimilar market.
1.Pfizer
Pfizer is a leading American pharmaceutical company which is operating in the field of generics or original drugs for more than 30 years. But did you know that this pharma not only manufactures biologics but also biosimilar drugs?
Pfizer has been in the business of biosimilar drugs for more than 10 years and have been quite successful as well. With more than 83,000 employees and presence in over 180 countries, this leading pharmaceutical company made almost USD 2 Bn. revenue only from its Biosimilar drugs sale in 2021.
Recently, this pharmaceutical company also collaborated with Samsung in two deals to produce various biosimilar drugs in South Korea. The deal size between these two companies happens to be approximately USD 900 Bn.
The major Biosimilar drugs of this pharmaceutical giant are primarily
ZIRABEV (a Biosimilar of Avastin)
TRAZIMERA (a Biosimilar of Herceptin)
RUXIENCE (a Biosimilar of Rituxan)
RITACRIT (a Biosimilar of Epogen)
NVYEPRIA (a Biosimilar of Neulasta)
NIVESTYM (a Biosimilar of Neupogen)
FILGRASTIM (a Biosimilar of Neupogen).
Click here to Download a Sample Report
https://www.kenresearch.com/sample-report.php?Frmdetails=NTk2NjM4
2.Amgen
Amgen is another leading American pharmaceutical company which not only makes Biologics or generic drugs but also Biosimilar drugs. This pharmaceutical company has more than 40 years of experience when it comes to pharmaceutical line.
With over 25000 employees and presence in over 100 countries, this pharmaceutical company earned about USD 2 Bn. from their three biosimilar drugs which are reportedly MVASI, KANJITNTI, and AMJEVITA.
This pharma giant has also invested about USD 2 Bn. in the development of Biosimilar drugs.
This pharmaceutical company has made Biosimilar drugs primarily in 4 fields which are General Medicine, Oncology, and Hematology along with, Inflammation.
EPOTEIN ALFA
AMJEVITA
AVSOLA
KANJINTI
MVASI
RIABNI
are the various Biosimilar drugs of Amgen. And, STELARA, EYLEA, SOLIRIS are in their pipeline.
Recently Amgen revealed their Biosimilar report's 8 version. It revealed a major information which said that the pharmaceutical company saved about USD 10 Bn. through their Biosimilar drugs in the past five years.
3.Viartis
Headquartered in Canonsburg, Pennsylvania, this American pharmaceutical company was founded only in 2020 yet they have achieved massive success in the pharmaceutical products with their revenue being USD 16 ~Bn. in 2022.
With presence in 165 countries and with over 45,000 employees worldwide, this pharmaceutical company makes pharmaceutical products in 10 areas which primarily are Cardiovascular, Dermatology, ophthalmology, Oncology, Gastroenterology, Women's health, Infectious diseases, Diabetes & Metabolism, Immunology, CNS & Anesthesiology, Respiratory diseases and allergy.
Speaking of their first Biosimilar products, their first ever Biosimilar drug was launched in 2014. They have a variety of Biosimilar drugs which are primarily
TRASTUZUMAB
INSULIN ASPART
PEGFILGRASTIM
INSULIN GLARGINE-YFGN
ADALIMUMAB
BEVACIZUMAB
Their Biosimilar drug Insulin Glargine which is known as SEMGLEE was the first ever interchangeable Biosimilar drug in the United States which was FDA approved.
Their PEGFILGRASTIM also was the first ever FDA approved drug in the United States. They have launched their Biosimilar drugs in over 75 markets worldwide.
Click here to Ask for a Custom Report
https://www.kenresearch.com/ask-customization.php?Frmdetails=NTk2NjM4
4.Coherus Biosciences:
Headquartered in Redwood city, California this American pharmaceutical company earned a revenue of almost USD 211 Mn. In 2022.
With presence in over 55 countries and 300+ employees worldwide, this pharmaceutical company makes products in various areas such as solid tumors, non-small lung cancers, nasopharyngeal carcinoma, small cell lung cancer and hepatocellular carcinoma.
Speaking of their Biosimilar drugs, this pharma has been in the field of creating Biosimilar drugs since 2010 which has given them almost 13 years of experience.
This pharmaceutical company also disclosed that it plans to spend at least USD 1 Tn. on medicines worldwide, out of which at least 40% will be spent on Biosimilar drugs.
Their three major Biosimilar drugs which are also FDA approved include UDENCYA, YUSIMRY, and CIMERLI.
Udencya is a Biosimilar drug of Pegfilgrastim, Yusimry is a Biosimilar drug of Ranibizumab, and Cimerli is a Biosimilar drug of Adalimumab.
Visit This Link for Detailed Report
https://www.kenresearch.com/industry-reports/us-biosimilar-market
5.Biogen
Headquartered in Cambridge, Massachusetts, this American pharmaceutical company earned a revenue of around USD 10 Bn. in 2022.
This company happens to have an experience of more than 40 years when it comes to making pharmaceutical products.
With presence in over 80 countries and more than 9000 employees worldwide, this pharmaceutical company primarily deals in Neurology, Specialized Immunology, Neuropsychiatry, Ophthalmology, and Rare Diseases.
ADUCANUMAB
LECANEMAB
TOFERSEN
ZURANOLONE
LITIFILIMAB
BENAPALI
FLIXABI
IMRALDI
are some of their Biosimilar drugs.
With their Biosimilar drugs, more than 250,000 people have gone on Anti-Tumor Necrosis Factor therapy.
Recently, this pharmaceutical company also made an agreement with Bio-Thera solutions to develop a Biosimilar drug for the treatment of Rheumatoid Arthritis.
India
Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49 Gurgaon, Haryana - 122001, India
Based out of India, Indonesia and UAE. Since 2011, we have been assisting clients globally with our Syndicate and Bespoke Market Research and Advisory Services.
Our Solutions are driven by qualitative and quantitative evaluation of markets across diverse Sectors and Geographies. We assist clients in their objectives related to market entry, product pricing, Product-fit evaluation, competition benchmarking, forecasting business planning and financial planning.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Top 5 players in US Biosimilar Market here
News-ID: 3266568 • Views: …
More Releases from Ken Research
Top Players Are Reshaping the India Telemedicine Market: Who's Leading and Why I …
In 2024, the India Telemedicine market was valued at USD 2.3 Bn, dominated by players such as Practo and Apollo TeleHealth due to their extensive doctor networks and full-stack digital infrastructure. From strategic acquisitions to AI-driven platforms, these leaders are setting new standards for virtual care delivery across India.
New Delhi, April 14, 2025
Ken Research's latest Competitive Landscape Report 2025 on the India Telemedicine Market dissects how dominant players…

Smart Parking for Smart Cities: Unveiling the Future of US Parking Management
What is the Size of US Parking Management Industry?
US Parking Management industry is growing at a CAGR of ~% in 2017-2022 and is expected to reach ~USD Bn by 2028. The parking management in the United States is a substantial industry, driven by factors such as urbanization, increasing vehicle ownership & the need for efficient parking solutions.
The market consists of various types of parking facilities: on-street parking, off-street parking lots,…

The Transformative Growth of the US Acute Myeloid Leukemia Market
What is the Size of US Acute Myeloid Leukemia Industry?
US Acute Myeloid Leukemia Market is expected to grow at a CAGR of ~ % in 2022 and is expected to reach ~USD Mn by 2028. The US Acute Myeloid Leukemia market is the rapid advancement in precision medicine and targeted therapies. The emergence of innovative treatments tailored to the genetic and molecular characteristics of individual AML patients has transformed the…

Shaping the Future of USA Solid Tumor Therapeutics Market
What is the Size of USA Solid Tumor Therapeutics Industry?
USA Solid Tumor Therapeutics Market is expected to grow at a CAGR of ~% between 2022-2028 and is expected to reach ~USD Bn by 2028. The development of novel therapies like immunotherapies (checkpoint inhibitors, CAR-T cells), targeted therapies (kinase inhibitors, monoclonal antibodies), and precision medicine approaches has revolutionized solid tumor treatment, offering more effective and personalized options. Researchers are increasingly exploring…
More Releases for Biosimilar
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Infliximab Biosimilar Insight, 2023 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2023" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…